| Mgmt Confidence | Confident in Japan approval; cautious on US de novo pathway timelines. |
|---|---|
| Demand Visibility | Identified 300,000 potential ischemic heart failure patients in Japan. |
| Margin Trends | R&D expenses decreased to $3.4 million YTD from $3.8 million. |
| Op. Leverage | Annual burn rate maintained at approximately $6 million while running Phase 3. |
| Pricing Power | Noted peer therapy reimbursement in Japan at over $300,000 per treatment. |
| Segment Growth | Japan initial indication targeting 20,000 patients post-approval. |
| New Clients | Four gene therapy collaboration conversations held in the last 72 hours. |
| Capex & Debt | Ended quarter with $2.2 million cash and cash equivalents. |
| Regulatory | PMDA submission pending; FDA de novo submission expected Q1 2027. |
| Commentary | Focusing on autologous cell therapy to align with Japanese cultural preferences. |
| New Launches | Helix Transcendental delivery system US launch targeted for mid-2027. |
Growth
Net loss decreased to $5.7 million year-to-date from $6.2 million in 2025.
Outlook
Targeting Japan approval mid-2027 for 20,000 initial patients; US Helix approval mid-2027.
Risks
Management evaded specific enrollment numbers for CHF II trial, citing focus on regulatory priorities.
The company's earnings call, NASDAQ: BCDA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
BioCardia, Inc.: key numbers
- Share price
- $0.7901Close, Nov 16
- Market cap
- $12M
- Shares outstanding
- 15.14MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BioCardia, Inc.
All →BioCardia Financial Results
BioCardia reported financial results for the third quarter ended September 30, 2026, and provided updates on its regulatory progress in Japan and the U.S. The company successfully completed pre-submission interactions with Japan's PMDA for its CardiAMP cell therapy and expects to file for FDA De Novo approval of its Helix delivery system in Q1 2027.
“We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
“In addition, in the coming months, we aim to be able to submit our Helix transendocardial delivery platform for FDA approval, which would be the first delivery system of its type approved in the United States. This promises to be an exciting year ahead.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
BioCardia Q3 2026 Results: Net Loss of $1.82M, Loss Widens
BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.
- Key figure
- Net loss $1.82M
BioCardia Business Update
BioCardia has completed the clinical consultation process with Japan's PMDA regarding application materials for its CardiAMP Cell Therapy System. This milestone allows the company to advance toward a formal marketing approval application for the treatment of ischemic heart failure in Japan, with initial patient treatments and commercial revenues targeted for 2028.
- Counterparty
- Pharmaceuticals and Medical Devices Agency (PMDA)
BioCardia Business Update
BioCardia announced that the FDA has accepted its revised De Novo pre-submission package for the marketing clearance of its Helix transendocardial delivery catheter. The company expects a substantive review and a meeting with the FDA to discuss the approval pathway during the current quarter.
BioCardia Clinical Trial Data
BioCardia announced it will present the trial design and scientific support for its CardiAMP HF II Study at the Heart Failure Society of America Annual Scientific Meeting. The study evaluates a high-dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF) who remain symptomatic despite medical therapy.
- Counterparty
- Heart Failure Society of America
BioCardia Business Update
BioCardia has submitted a revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) for the approval of its Helix Catheter for therapeutic and diagnostic delivery to the heart. The submission incorporates prior FDA feedback regarding marketing clearance pathways and safety data, with the FDA expected to provide written feedback or hold a meeting within 70 days. An independent clearance would allow BioCardia to partner with other developers of cell, gene, and protein therapeutics requiring targeted cardiac delivery.
- Counterparty
- FDA